Allogeneic stem-cell transplantation for renalcellcancer

Gommersall, Lyndon; Hayne, Dickon; Lynch, Ciarán C.; Joseph, Jean; Arya, Manit; Patel, Hitendra

doi:10.1016/s1470-2045(04)01568-2

Cited by 13 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is therefore not recommended outside a clinical trial setting. (Barkholt et al, 2006;Gommersall et al, 2004;Rini et al, 2002) Patients with good prognostic features had a response rate of 10-20% to IFN-and IL-2 and a modest improvement of median survival by ~2.5 months with IFN-. (1999;Coppin et al, 2005) High dose IL-2 (infusion therapy requiring hospitalization) conferred a durable but small long term disease remission of ~5% in clinical responders.…”

Section: Systemic Treatment Of Metastatic Renal Cell Carcinomamentioning

confidence: 99%

“…(Gommersall et al, 2004) A randomized phase II trial randomized 116 patients with metastatic clear-cell RCC to either placebo, low-dose (3 mg/kg given fortnightly) or high-dose bevacizumab (10 mg/kg given fortnightly). Accrual was halted when an interim analysis revealed a time to disease progression (TTP) benefit in the (high-dose) bevacizumab arm.…”

Section: Bevacizumabmentioning

confidence: 99%

See 1 more Smart Citation

New Systemic Approaches in the Treatment of Metastatic Renal Cell Carcinoma

Tan¹,

Lees²,

Pranavan³

et al. 2012

Emerging Research and Treatments in Renal Cell Carcinoma

View full text Add to dashboard Cite

Section: Systemic Treatment Of Metastatic Renal Cell Carcinomamentioning

confidence: 99%

Section: Bevacizumabmentioning

confidence: 99%

New Systemic Approaches in the Treatment of Metastatic Renal Cell Carcinoma

Tan¹,

Lees²,

Pranavan³

et al. 2012

Emerging Research and Treatments in Renal Cell Carcinoma

View full text Add to dashboard Cite

“…Metastatic RCC is relatively refractory to chemotherapy therapy 1 rendering it a challenging tumor to treat. Prior to the era of targeted therapies, systemic therapies of inoperable metastatic RCC were limited to immunomodulatory or cytokine therapies with interferon alpha (IFN‐α), interleukin (IL‐2) and the more investigational allogeneic stem‐cell transplantation by use of mobilized, CD34‐positive, peripheral‐blood stem cells from a matched donor 12 …”

Section: Systemic Therapiesmentioning

confidence: 99%

New systemic treatment options for metastatic renal‐cell carcinoma in the era of targeted therapies

Tan

Pranavan

Haxhimolla

et al. 2010

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Advances in understanding the biology and genetics of renal-cell carcinomas have led to the development of novel targeted therapies for the treatment of metastatic renal-cell cancer. Previously the systemic approaches were limited to cytokine therapies that were modest in their clinical benefits and at the expense of significant toxicities. Investigational treatments with allogeneic bone marrow transplantation were equally toxic and resulted in significant morbidity and mortality. The development of targeted therapy has revolutionized the treatment of metastatic renal-cell cancer with more meaningful outcomes. This review aims to provide a detailed discussion of the clinical benefits of targeted therapies such as sunitinib, sorafenib, temsirolimus, everolimus, bevacizumab, and some of the newer agents in clinical trial development. The efficacy of these compounds in terms of response, survival and clinical benefit are explored as well as their toxicities. The role of surgery in metastatic renal-cell carcinoma is reviewed in the context of cytoreductive therapy and resection of solitary and oligometastatic disease. Ongoing studies in the adjuvant setting following curative resection are also reviewed. The availability of targeted therapies has led to their rapid adoption as frontline therapy over traditional cytokine therapy, thus bringing more optimistic and hopeful therapeutic options in a condition where historically, systemic treatments have been relatively unsatisfactory and disappointing.

show abstract

“…1 Although immunotherapy with cytokines such as interleukin 2 and interferon alpha can lead to regression of RCC in some patients, the response rate for these treatments remains around 10-20%, and response is usually temporary. 2 Recently, allogeneic stem cell transplantation utilizing mobilized peripheral blood from a matched donor has been investigated as an alternative immunotherapeutic strategy for the treatment of advanced RCC.…”

Section: Introductionmentioning

confidence: 99%

“…The results of pilot reduced-intensity transplant trials for metastatic RCC are encouraging and show that responses can occur in patients with advanced metastatic disease that has failed to respond to conventional cytokine-based therapy. 1,[3][4][5][6][7][8][9][10][11][12][13][14][15] Unrelated cord blood (UCB) is considered an alternative hematopoietic stem cell source for transplantation, and its use in adult patients with hematologic disorders is increasing. [16][17][18][19][20][21] Thus far, UCB transfer has not been attempted in patients with a solid-organ malignancy such as RCC.…”

Section: Introductionmentioning

confidence: 99%